NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/matthew-perrone-ap-business-writers
Sign In To follow
Drugmaker Vivus Inc. said Monday that regulators will take another three months to make a decision on its closely-watched obesity drug Qnexa, which could become the first new prescription drug to reach the market in more than a decade.